New drug combo aims to fight colorectal cancer when standard chemo fails
NCT ID NCT07286695
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a new drug combination (fruquintinib plus trifluridine/tipiracil) works better than a standard combo (bevacizumab plus trifluridine/tipiracil) for people with advanced colorectal cancer that has not responded to standard chemotherapy. About 292 adults aged 18-75 will be randomly assigned to one of the two treatments. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib combined with trifluridine/tipiracil
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard chemotherapy options.
What could go wrong
This is an early Phase 2 trial with only 292 participants, so results may not confirm benefit. The combination may cause side effects like those seen with similar drugs, and it may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100000, China
Contact Email: •••••@•••••